SPRY4 Human

Sprouty Homolog 4 Human Recombinant
Shipped with Ice Packs
In Stock

Description

Introduction to SPRY4 Human

SPRY4 (Sprouty RTK Signaling Antagonist 4) is a protein-coding gene located on chromosome 5q31.3 in humans, encoding a 322-amino acid intracellular protein with a molecular weight of approximately 32.5 kDa . It belongs to the Sprouty family of proteins, which are cysteine- and proline-rich negative regulators of receptor tyrosine kinase (RTK) signaling pathways, particularly the mitogen-activated protein kinase (MAPK) pathway . SPRY4 functions as a feedback inhibitor of growth factor signaling, modulating cellular processes such as proliferation, migration, apoptosis, and oxidative stress .

Molecular Structure and Functional Domains

SPRY4 contains conserved structural domains critical for its regulatory functions:

DomainFunctionKey Features
C-Terminal CRDMembrane translocation and inhibition of MAPK signalingCysteine-rich domain (CRD) binds Raf1 and PIP2, disrupting SOS1/Grb2 interactions
N-Terminal CBDInteraction with c-Cbl and other adaptorsContains tyrosine residues critical for FGF signaling inhibition
PEST SequenceRegulates protein stability and degradationProline (P), glutamic acid (E), serine (S), threonine (T)-enriched motif

The PEST sequence accelerates SPRY4 degradation, while its CR domain binds phosphatidylinositol bisphosphate (PIP2), blocking PLCγ hydrolysis and downstream PKC/Ca²⁺ signaling .

Signaling Pathways and Functional Regulation

SPRY4 modulates multiple signaling cascades:

MAPK Pathway Inhibition

SPRY4 binds free SOS1 or the Grb2-SOS1 complex, preventing Ras activation and suppressing ERK phosphorylation . This inhibition is context-dependent:

  • FGF Signaling: Disrupts FGF-induced ERK activation via SOS1 sequestration .

  • Vascular Endothelial Growth Factor (VEGF): Binds Raf1 to inhibit VEGF-A-induced ERK signaling .

  • Sphingosine-1-Phosphate (S1P): Suppresses S1P/PLCγ/PKC and AKT pathways .

Crosstalk with Other Pathways

PathwayMechanismOutcome
GPCR SignalingBinds PIP2, blocking PLCγ hydrolysis and Ca²⁺ mobilization Inhibits PKD and ERK activation
Integrin SignalingRepresses TESK1-mediated cofilin phosphorylation via inhibition of cell spreading Limits cytoskeletal remodeling

Cancer

SPRY4 exhibits dual roles as a tumor suppressor or oncogene, depending on context:

Cancer TypeSPRY4 FunctionMechanism
Colorectal CancerTumor suppressor; inhibits proliferation via EZH2/MDM2/p53 pathway Downregulates EZH2, promoting p53-mediated apoptosis
GlioblastomaOncogene; promotes survival under hypoxic conditions Modulates HIF-1α/VEGF pathways
Osteoarthritis (OA)Protective role; inhibits chondrocyte hypertrophy Suppresses RUNX2, COL10, and MMP13 expression

Osteoarthritis

SPRY4 expression is higher in healthy cartilage and decreased in OA, correlating with disease severity . Knockdown in healthy chondrocytes induces hypertrophy, senescence, and ECM degradation, while overexpression in degenerated chondrocytes restores glycosaminoglycan (GAG) content and reduces ECM proteases (e.g., MMP13, ADAMTS5) .

Therapeutic Potential

ApplicationStrategyOutcome
Cancer TherapyOverexpression or small-molecule mimeticsInhibits tumor growth in CRC, glioblastoma
OA TreatmentLentiviral SPRY4 deliveryPrevents chondrocyte hypertrophy; preserves cartilage

Expression Patterns

SPRY4 is widely expressed in human tissues, with high RNA/protein levels observed in:

TissueRNA ExpressionProtein Expression
LungHigh (GTEX data) High (Human Protein Atlas)
KidneyHigh (GTEX data) Moderate (Human Protein Atlas)
Adipose TissueHighest (GTEX data) Low (Human Protein Atlas)

Product Specs

Introduction
Sprouty Homolog 4 (SPRY4) is a negative regulator of the receptor-activated mitogen-activated protein kinase (MAPK) signaling pathway, acting at a point upstream of RAS activation. Among its various functions, SPRY4 protein is known to inhibit the EGFR-mediated MAPK signaling pathway and disrupt the formation of GTP-Ras.
Description
Recombinant human SPRY4, expressed in E. coli, is a single, non-glycosylated polypeptide chain comprising 322 amino acids (residues 1-299) with a molecular weight of 34.9 kDa. It includes a 23 amino acid His-tag fused at the N-terminus and is purified using proprietary chromatographic methods.
Physical Appearance
Sterile, colorless, and filtered solution.
Formulation
The SPRY4 solution is supplied at a concentration of 1 mg/ml and is formulated in a buffer containing 20 mM Tris-HCl (pH 8.0), 10% glycerol, and 0.4 M Urea.
Stability
For short-term storage (2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advised for long-term storage. Repeated freezing and thawing should be avoided.
Purity
Purity is determined to be greater than 85.0% as assessed by SDS-PAGE analysis.
Synonyms
Protein sprouty homolog 4, SPRY4, Sprouty Homolog 4, Spry-4, Protein sprouty homolog 4 isoform 2, Sprouty homolog 4 (Drosophila).
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMEPPIPQ SAPLTPNSVM VQPLLDSRMS HSRLQHPLTI LPIDQVKTSH VENDYIDNPS LALTTGPKRT RGGAPELAPT PARCDQDVTH HWISFSGRPS SVSSSSSTSS DQRLLDHMAP PPVADQASPR AVRIQPKVVH CQPLDLKGPA VPPELDKHFL LCEACGKCKC KECASPRTLP SCWVCNQECL CSAQTLVNYG TCMCLVQGIF YHCTNEDDEG SCADHPCSCS RSNCCARWSF MGALSVVLPC LLCYLPATGC VKLAQRGYDR LRRPGCRCKH TNSVICKAAS GDAKTSRPDK PF.

Q&A

What is SPRY4 and what is its primary function in human cells?

SPRY4 belongs to the Spry family of proteins that are rich in cysteine and proline. It functions primarily as an inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway . As an intracellular protein, SPRY4 translocates to the plasma membrane upon activation, with its structural domain located in the cytoplasmic membrane . With a molecular weight of approximately 32.541 KDa, SPRY4 is involved in various cellular biological functions including embryonic development, organogenesis, cell apoptosis and proliferation, oxidative stress, inflammatory response, and ischemic injury under both physiological and pathological conditions .

What are the structural characteristics of the SPRY4 protein?

SPRY4 is characterized by several key structural features:

FeatureDetails
Gene SymbolhSPRY4 (human), mSPRY4 (mouse)
Chromosome Location5q31.3 (human), 18 B3 (mouse)
Molecular Weight32.6 kDa
Protein Isoelectric Point8.25

The protein contains a shared C-terminal cysteine-rich domain that is characteristic of the SPRY family . Mammalian SPRY proteins can form cooperative homo- and hetero-oligomers, which contribute to their regulatory functions . The protein structure is particularly rich in cysteine and proline residues, which are important for its functional properties .

How does SPRY4 interact with the MAPK signaling pathway?

SPRY4 suppresses ERK MAPK activity induced by multiple growth factors, including FGF, vascular endothelial cell growth factor, and nerve growth factor in various cell types . Its point of action within the signaling cascade can be cell type-specific and growth factor-specific, but it primarily acts at the level of RAS and/or RAF1 .

Experimental evidence demonstrates that induction of SPRY4 by FGF2 or GDNF can be completely abrogated by chemical inhibitors of MEK1/2 but not by inhibitors of other canonical pathways (PI3K, PKC, p38 MAPK, or JNK MAPK), indicating relative specificity for the ERK MAPK pathway . When SPRY4 is disrupted via CRISPR/Cas9 gene editing, cells exhibit increased ERK activity within minutes of exposure to FGF2, suggesting that even low basal levels of SPRY4 are sufficient to regulate ERK MAPK signaling .

What methods are commonly used to study SPRY4 expression in human tissues?

Several complementary methodologies are employed to study SPRY4 expression:

  • RNA expression profile analysis through databases like the Genotype-Tissue Expression Project

  • Immunohistochemical staining of tissue sections to detect protein localization

  • Reporter systems such as the H2B-Venus fluorophore to visualize SPRY4-expressing cells in situ

  • Quantitative single-cell analysis using specialized reporter systems like ERK-KTR

  • CRISPR/Cas9 gene editing for functional studies of SPRY4

  • Co-immunostaining with relevant markers (e.g., GFRA1, MCAM) to identify specific SPRY4-expressing cell populations

How is SPRY4 expression regulated in different human tissues?

Analysis of RNA expression profiles shows that SPRY4 is widely expressed across human tissues . The regulation of SPRY4 appears to be tissue-specific and context-dependent. At the transcriptional level, growth factors like FGF2 or GDNF can induce SPRY4 expression through the ERK MAPK pathway, as demonstrated by the complete abrogation of this induction by MEK1/2 inhibitors .

In the context of spermatogonial stem cells, SPRY4 expression decreases during differentiation, suggesting a developmental regulation of its expression . The use of a nuclear-localized SPRY4 reporter (H2B-Venus) has revealed that SPRY4 is expressed not only in certain germ cells but also in various somatic cell types, including peritubular, Leydig, endothelial, and Sertoli cells, though with varying intensity .

How does SPRY4-dependent ERK negative feedback regulate stem cell fate in the human germline?

Research demonstrates that growth factor signaling through the ERK MAPK pathway in spermatogonial stem cells is tightly regulated within a narrow range through distinct intracellular negative feedback regulators, including SPRY4 . Undifferentiated spermatogonia in vivo exhibit high levels of SPRY4 mRNA . When SPRY4 is ablated, disruption of ERK MAPK signaling downstream of RAS occurs, leading to a shift in cell fate toward early differentiation with concomitant loss of stem cell activity .

Using a mouse SPRY4 reporter line, researchers have shown that the adult spermatogonial stem cell population in vivo is demarcated by strong SPRY4 promoter activity . Specifically, SPRY4 is expressed in A single, A pair, and A aligned undifferentiated spermatogonia, with A single spermatogonia considered to be the primary SSC-containing population .

How can single-cell RNA sequencing data be effectively analyzed to understand SPRY4's role in cellular differentiation?

Single-cell RNA sequencing (scRNA-seq) provides powerful insights into SPRY4's role in cellular differentiation through several analytical steps:

  • Data processing and quality control:

    • Alignment of reads to the reference genome (e.g., mm10-2020-A) using Cell Ranger

    • Demultiplexing using cell barcodes and unique molecular identifiers (UMIs)

    • Quality filtering to remove outlier cells based on gene number, transcript number, and mitochondrial RNA percentage

  • Normalization and dimension reduction:

    • Normalization and log-transformation of gene expression counts using SCTransform in Seurat

    • Selection of top variable genes (e.g., 2000) for principal component analysis

    • Generation of Uniform Manifold Approximation and Projection (UMAP) using top principal components

  • Cell-type identification:

    • Use of the SingleR package with reference databases for initial annotation

    • Manual annotation based on established markers (e.g., MCAM/Id4/Gfra1 for stem cells; Sox3/Nanos3/Kit/Stra8 for differentiated cells)

    • Regression of cell cycle scores to minimize confounding effects

  • Trajectory analysis:

    • Construction of developmental trajectories using algorithms like Monocle3

    • Application of reversed graph embedding to learn gene expression sequence changes

    • Construction of "branched" trajectories corresponding to cellular "decisions"

    • Selection of appropriate nearest neighbor graphs for Leiden community detection

This methodological approach has successfully identified distinct spermatogonial cell populations with varying SPRY4 expression levels, revealing its role in maintaining stem cell identity versus promoting differentiation .

How do SPRY4 variants contribute to human infertility and embryonic arrest?

A heterozygous variant in the SPRY4 gene has been identified in infertile patients and is associated with early embryonic arrest in humans . Researchers have conducted both in vitro and in vivo studies to investigate the effects of this pathogenic variant .

The study identified a pathogenic SPRY4 variant as a genetic factor contributing to early embryonic arrest in infertile patients . This finding suggests that proper SPRY4 function is essential for early embryonic development, and disruption through genetic variants can lead to developmental arrest and subsequent infertility .

The precise mechanisms likely involve dysregulation of the MAPK signaling pathway, which is normally inhibited by SPRY4. Since SPRY4 plays important roles in embryonic development and organogenesis , alterations in its function could disrupt critical developmental processes necessary for successful embryo formation.

What are the best methods for investigating SPRY4's interaction with RAS/RAF in the ERK MAPK pathway?

To investigate SPRY4's interaction with RAS/RAF in the ERK MAPK pathway, several methodological approaches have proven effective:

  • Genetic manipulation:

    • CRISPR/Cas9 gene editing to disrupt the SPRY4 coding sequence, resulting in increased ERK activity upon growth factor stimulation

    • Generation of specific mutations or deletions to identify functional domains involved in RAS/RAF interaction

  • Signaling dynamics analysis:

    • Use of the ERK-KTR (Kinase Translocation Reporter) system to analyze dynamic ERK activity at the single-cell level

    • Time-course experiments following growth factor stimulation to capture immediate and delayed effects

  • Pathway specificity determination:

    • Application of chemical inhibitors for specific pathway components (MEK1/2, PI3K, PKC, p38 MAPK, JNK MAPK) to isolate SPRY4's effect on the ERK MAPK pathway specifically

    • Comparison of multiple growth factors (FGF2, GDNF) to identify factor-specific effects

  • Molecular localization:

    • Examination of SPRY4 translocation to the plasma membrane upon activation

    • Co-localization studies with RAS/RAF components using immunofluorescence or advanced microscopy techniques

These approaches collectively provide a comprehensive understanding of how SPRY4 regulates the ERK MAPK pathway at the level of RAS/RAF, with implications for growth factor-dependent cellular processes .

What experimental approaches are most effective for studying SPRY4's role in embryonic development?

Based on the research methodologies described in the search results, several experimental approaches have proven effective for studying SPRY4's developmental roles:

  • Reporter systems:

    • Development of nuclear-localized SPRY4 reporters (such as H2B-Venus) to visualize SPRY4-expressing cells during development

    • This approach allows for sensitive, transcriptional read-out of SPRY4 promoter activity in developing tissues

  • Immunostaining techniques:

    • Whole-mount immunostaining to identify SPRY4-expressing cells in intact tissues

    • Co-immunostaining with developmental markers (e.g., GFRA1, MCAM, DAZL) to correlate SPRY4 expression with specific cell types

  • Genetic manipulation:

    • CRISPR/Cas9-mediated gene editing to study loss-of-function phenotypes

    • Creation of specific mutations to understand structure-function relationships

  • Quantitative analysis:

    • Scoring of cell populations in tissue sections using confocal microscopy

    • Statistical analysis to determine the extent of overlap between SPRY4-expressing cells and other marker-positive populations

  • Single-cell transcriptomics:

    • scRNA-seq to identify developmental trajectories and SPRY4-dependent gene expression patterns

    • Pseudotime analysis to place SPRY4-expressing cells along developmental continuums

These approaches have successfully revealed SPRY4's importance in maintaining stem cell populations and regulating differentiation during development, particularly in the context of the mammalian germline .

Product Science Overview

Discovery and Evolution

Sprouty proteins were first discovered in Drosophila melanogaster (fruit fly) as inhibitors of fibroblast growth factor (FGF)-mediated tracheal branching . The human homologs of Sprouty, including SPRY4, were identified later. SPRY4 is located on chromosome 5q31.3 in humans .

Function and Mechanism

SPRY4 functions as an inhibitor of the receptor-transduced mitogen-activated protein kinase (MAPK) signaling pathway . It is positioned upstream of RAS activation and impairs the formation of active GTP-RAS . By doing so, SPRY4 suppresses the epidermal growth factor receptor (EGFR)-transduced MAPK signaling pathway . This inhibition is crucial for regulating cellular responses to growth signals and maintaining cellular homeostasis.

Biological Significance

The MAPK/ERK signaling pathway, regulated by SPRY4, is one of the most widespread regulatory mechanisms in eukaryotic cell biology . Dysregulation of this pathway can lead to various diseases, including cancer. Therefore, SPRY4’s role as a negative regulator is vital for preventing uncontrolled cell proliferation and tumorigenesis.

Research and Applications

Human recombinant SPRY4 is used in research to study its inhibitory effects on MAPK signaling and its potential therapeutic applications. Understanding SPRY4’s function and regulation can provide insights into developing targeted therapies for diseases associated with aberrant RTK signaling.

Interactions

SPRY4 has been shown to interact with various proteins, including TESK1 . These interactions further modulate its inhibitory effects on signaling pathways, highlighting the complexity of its regulatory mechanisms.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.